In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:
- Hepatitis B
- Prevention of HBV vertical transmission when HBIg is unavailable
- Therapeutic vaccination for HBV cure
- Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
- Hepatitis delta
- HDV prevalence in ethnically diverse, urban, safety-net populations
- Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
- Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
- HDV functional cure with lonafarnib-based therapy
- Hepatitis C
- Integrated community HCV service for PWUD: the ITTREAT study
- Helios-3 study of treatment of people with HCV by specialists or nonspecialists
- Risk of HCC after SVR in patients with HCV
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Follow along with the downloadable slideset at:
https://bit.ly/3FxIOwZ
Link to full program:
https://bit.ly/3Y1tD6f
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
